VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 137 filers reported holding VANDA PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,064,541 | -89.1% | 477,903 | -64.4% | 0.69% | -94.7% |
| Q2 2019 | $18,908,000 | -18.5% | 1,341,943 | +6.5% | 13.02% | -2.4% |
| Q1 2019 | $23,189,000 | +301.8% | 1,260,288 | +470.7% | 13.34% | +163.2% |
| Q4 2018 | $5,771,000 | -22.5% | 220,848 | -32.0% | 5.07% | +16.3% |
| Q3 2018 | $7,450,000 | -34.8% | 324,600 | -45.9% | 4.36% | -37.3% |
| Q2 2018 | $11,430,000 | -31.1% | 600,000 | -39.1% | 6.94% | -21.9% |
| Q1 2018 | $16,590,000 | +23.3% | 984,584 | +11.3% | 8.89% | +10.3% |
| Q4 2017 | $13,452,000 | +150.5% | 885,000 | +195.0% | 8.06% | +154.7% |
| Q3 2017 | $5,370,000 | -51.9% | 300,000 | -56.2% | 3.16% | -47.5% |
| Q2 2017 | $11,167,000 | +1742.7% | 685,086 | +1482.2% | 6.03% | +1663.2% |
| Q1 2017 | $606,000 | -93.3% | 43,300 | -94.7% | 0.34% | -96.3% |
| Q2 2016 | $9,081,000 | -47.5% | 811,563 | -60.8% | 9.31% | -54.3% |
| Q1 2016 | $17,291,000 | -3.2% | 2,068,297 | +7.8% | 20.39% | -2.6% |
| Q4 2015 | $17,865,000 | – | 1,918,929 | – | 20.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,791,805 | $64,992,000 | 3.92% |
| Birchview Capital, LP | 80,000 | $1,371,000 | 0.93% |
| Profit Investment Management, LLC | 78,154 | $1,339,000 | 0.93% |
| Soleus Capital Management, L.P. | 298,600 | $5,118,000 | 0.80% |
| GLOBEFLEX CAPITAL L P | 196,026 | $3,360,000 | 0.73% |
| DENALI ADVISORS LLC | 89,300 | $1,531,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 1,965,000 | $33,680,000 | 0.57% |
| FinTrust Capital Advisors, LLC | 105,982 | $1,816,000 | 0.48% |
| Zebra Capital Management LLC | 22,878 | $392,000 | 0.48% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 124,000 | $2,125,000 | 0.47% |